- Home
- WU vs AXSM Comparison
WU vs AXSM Comparison
Compare WU & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WU
- AXSM
- Stock Information
- Founded
- WU 1851
- AXSM 2012
- Country
- WU United States
- AXSM United States
- Employees
- WU N/A
- AXSM N/A
- Industry
- WU Business Services
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- WU Consumer Discretionary
- AXSM Health Care
- Exchange
- WU Nasdaq
- AXSM Nasdaq
- Market Cap
- WU 3.6B
- AXSM 4.2B
- IPO Year
- WU 2006
- AXSM 2015
- Fundamental
- Price
- WU $10.66
- AXSM $137.75
- Analyst Decision
- WU Hold
- AXSM Strong Buy
- Analyst Count
- WU 11
- AXSM 14
- Target Price
- WU $12.11
- AXSM $158.93
- AVG Volume (30 Days)
- WU 6.6M
- AXSM 1.1M
- Earning Date
- WU 02-04-2025
- AXSM 02-18-2025
- Dividend Yield
- WU 8.82%
- AXSM N/A
- EPS Growth
- WU 63.10
- AXSM N/A
- EPS
- WU 2.74
- AXSM N/A
- Revenue
- WU $4,209,700,000.00
- AXSM $385,693,000.00
- Revenue This Year
- WU $2.74
- AXSM $45.18
- Revenue Next Year
- WU $1.90
- AXSM $65.22
- P/E Ratio
- WU $3.89
- AXSM N/A
- Revenue Growth
- WU N/A
- AXSM 42.53
- 52 Week Low
- WU $10.04
- AXSM $64.11
- 52 Week High
- WU $14.19
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- WU 52.57
- AXSM 74.55
- Support Level
- WU $10.18
- AXSM $124.04
- Resistance Level
- WU $10.89
- AXSM $130.52
- Average True Range (ATR)
- WU 0.28
- AXSM 5.78
- MACD
- WU 0.03
- AXSM 1.11
- Stochastic Oscillator
- WU 46.24
- AXSM 96.07
About WU Western Union Company (The)
Western Union provides domestic and international money transfers through its global network of about 600,000 outside agents. The company handled over 270 million transactions in 2023 and is the largest money transfer company in the world.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.